Barinthus Biotherapeutics (BRNS) Cash & Equivalents (2021 - 2026)

Barinthus Biotherapeutics (BRNS) has 6 years of Cash & Equivalents data on file, last reported at $65.9 million in Q1 2026.

• Quarterly Cash & Equivalents fell 33.56% year-over-year to $65.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $65.9 million (down 33.56% YoY) and the FY2025 annual result came in at $70.5 million, down 36.33% from the prior year.
• Cash & Equivalents eased to $65.9 million in Q1 2026, from $70.5 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $200.6 million in Q1 2022 to a low of $65.9 million in Q1 2026.
• A 5-year average of $136.2 million and a median of $130.0 million in 2024 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents advanced 28.64% — and 2025, when it sank 36.33%.
• Tracing BRNS's Cash & Equivalents over 5 years: stood at $194.4 million in 2022, then declined by 26.9% to $142.1 million in 2023, then fell by 22.12% to $110.7 million in 2024, then sank by 36.33% to $70.5 million in 2025, then declined by 6.53% to $65.9 million in 2026.
• The last three Cash & Equivalents figures came in at $65.9 million (Q1 2026), $70.5 million (Q4 2025), and $74.3 million (Q3 2025), per Business Quant data.